OBJECTIVES: Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory disorders
of the gastrointestinal tract of unknown etiology. Evidence for treatment of the condition with …

Biological therapy revolutionized the treatment of inflammatory bowel disease (IBD) during
the last decade. These monoclonal antibodies, which target tumor necrosis factor (TNF) …

OBJECTIVES: Biologic therapies have been available for inflammatory bowel disease for>
20 years, but patient outcomes have not changed appreciably over this time period. To …

BACKGROUND & AIMS: Multiple randomized controlled trials (RCTs) have been conducted
to determine therapeutic efficacy of the biological agents for the inflammatory bowel …

Background Over the last decade, biologics have gained an important place for the
treatment of moderate to severe inflammatory bowel disease (IBD), and many randomized …

Objective To study the comparative efficacy of biologic therapy in the management of
biologic-naïve patients with Crohn disease (CD). Patients and Methods We conducted a …

The pharmacological management of inflammatory bowel disease (IBD) over the last two
decades has transitioned from reliance on aminosalycilates, corticosteroids and …

In the last decade, biologic agents, in particular anti-TNF agents such as infliximab,
adalimumab, and certolizumab have substantially extended the therapeutic armamentarium …

Background & Aims There is controversy regarding the best treatment for patients with
Crohn's disease because of the lack of direct comparative trials. We compared therapies for …

Aliment Pharmacol Ther 2011; 33: 870–879 Summary Background New medical therapies
have improved outlook in inflammatory bowel disease but published impact on surgical …